These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20979454)

  • 41. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season.
    Wkly Epidemiol Rec; 2007 Mar; 82(9):69-74. PubMed ID: 17333570
    [No Abstract]   [Full Text] [Related]  

  • 43. "Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?".
    Allwinn R; Bickel M; Lassmann C; Wicker S; Friedrichs I
    Med Microbiol Immunol; 2013 Apr; 202(2):125-30. PubMed ID: 22986732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections.
    Karunarathna HMTK; Perera RAPM; Fang VJ; Yen HL; Cowling BJ; Peiris M
    Emerg Microbes Infect; 2019; 8(1):404-412. PubMed ID: 30898033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.
    He XS; Sasaki S; Baer J; Khurana S; Golding H; Treanor JJ; Topham DJ; Sangster MY; Jin H; Dekker CL; Subbarao K; Greenberg HB
    J Infect Dis; 2013 Jan; 207(2):288-96. PubMed ID: 23107783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multivariate analysis of factors affecting the immunogenicity of trivalent inactivated influenza vaccine in school-age children.
    Freeman G; Ng S; Perera RA; Fang VJ; Ip DK; Leung GM; Peiris JS; Cowling BJ
    Epidemiol Infect; 2015 Feb; 143(3):540-9. PubMed ID: 24786933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seasonal inactivated influenza virus vaccines.
    Couch RB
    Vaccine; 2008 Sep; 26 Suppl 4(Suppl 4):D5-9. PubMed ID: 18602728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.
    Lee VJ; Tay JK; Chen MI; Phoon MC; Xie ML; Wu Y; Lee CX; Yap J; Sakharkar KR; Sakharkar MK; Lin RT; Cui L; Kelly PM; Leo YS; Tan YJ; Chow VT
    Vaccine; 2010 Oct; 28(42):6852-7. PubMed ID: 20723626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge.
    Jegaskanda S; Luke C; Hickman HD; Sangster MY; Wieland-Alter WF; McBride JM; Yewdell JW; Wright PF; Treanor J; Rosenberger CM; Subbarao K
    J Infect Dis; 2016 Sep; 214(6):945-52. PubMed ID: 27354365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.
    Subbramanian RA; Basha S; Shata MT; Brady RC; Bernstein DI
    Vaccine; 2010 Dec; 28(52):8258-67. PubMed ID: 21050903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China.
    Yang P; Zhang L; Shi W; Lu G; Cui S; Peng X; Zhang D; Liu Y; Liang H; Pang X; Wang Q
    Influenza Other Respir Viruses; 2012 Nov; 6(6):381-8. PubMed ID: 22212858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
    Rudraraju R; Mordant F; Subbarao K
    J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
    [No Abstract]   [Full Text] [Related]  

  • 59. Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines.
    Ohshima N; Iba Y; Kubota-Koketsu R; Yamasaki A; Majima K; Kurosawa G; Hirano D; Yoshida S; Sugiura M; Asano Y; Okuno Y; Kurosawa Y
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
    Onishchenko GG; Zverev VV; Katlinskiĭ AV; Semchenko AV; Korovkin SA; Mel'nikov SIa; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):15-9. PubMed ID: 17882832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.